Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early...
| Autores: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Recursos: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:256487 |
| Acesso em linha: | https://ddd.uab.cat/record/256487 https://dx.doi.org/urn:doi:10.1002/ueg2.12111 |
| Access Level: | acceso abierto |
| Palavra-chave: | Diarrhoea Hepatocellular carcinoma Resistance Sorafenib Survival Tyrosine kinase inhibitor |
| id |
ES_1f1913a862a0f3dd5b23cfc2fb3c831e |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:256487 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsDíaz-González, Álvaro|||0000-0003-3610-2263Sapena, Victor|||0000-0003-4379-6486Boix, Loreto|||0000-0002-6015-3901Torres, Ferran|||0000-0002-7355-7913Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705Da Fonseca, Leonardo G.|||0000-0002-0216-3618Llarch, Neus|||0000-0003-3209-0453Iserte, Gemma|||0000-0003-3908-8743Guedes, CassiaMuñoz-Martínez, S.|||0000-0003-0663-0575Darnell, AnnaBelmonte, Ernest|||0000-0003-3572-9769Rimola, Jordi|||0000-0002-1814-4198Forner, Alejandro|||0000-0002-9014-4950Ayuso, Carmen|||0000-0002-9606-6957Bruix, Jordi|||0000-0002-9826-0753Reig, María|||0000-0002-5711-9534DiarrhoeaHepatocellular carcinomaResistanceSorafenibSurvivalTyrosine kinase inhibitorDespite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/256487https://dx.doi.org/urn:doi:10.1002/ueg2.12111reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengMinisterio de Economía y Competitividad https://doi.org/10.13039/501100003329 CM15/00050Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19/00222Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI13/01229Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI15/00145Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/00542Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/00768Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/0358open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre i quan aquestes es distribueixin sota la mateixa llicència que regula l'obra original i es reconegui l'autoria.https://creativecommons.org/licenses/by-sa/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2564872026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| title |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| spellingShingle |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs Díaz-González, Álvaro|||0000-0003-3610-2263 Diarrhoea Hepatocellular carcinoma Resistance Sorafenib Survival Tyrosine kinase inhibitor |
| title_short |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| title_full |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| title_fullStr |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| title_full_unstemmed |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| title_sort |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| dc.creator.none.fl_str_mv |
Díaz-González, Álvaro|||0000-0003-3610-2263 Sapena, Victor|||0000-0003-4379-6486 Boix, Loreto|||0000-0002-6015-3901 Torres, Ferran|||0000-0002-7355-7913 Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705 Da Fonseca, Leonardo G.|||0000-0002-0216-3618 Llarch, Neus|||0000-0003-3209-0453 Iserte, Gemma|||0000-0003-3908-8743 Guedes, Cassia Muñoz-Martínez, S.|||0000-0003-0663-0575 Darnell, Anna Belmonte, Ernest|||0000-0003-3572-9769 Rimola, Jordi|||0000-0002-1814-4198 Forner, Alejandro|||0000-0002-9014-4950 Ayuso, Carmen|||0000-0002-9606-6957 Bruix, Jordi|||0000-0002-9826-0753 Reig, María|||0000-0002-5711-9534 |
| author |
Díaz-González, Álvaro|||0000-0003-3610-2263 |
| author_facet |
Díaz-González, Álvaro|||0000-0003-3610-2263 Sapena, Victor|||0000-0003-4379-6486 Boix, Loreto|||0000-0002-6015-3901 Torres, Ferran|||0000-0002-7355-7913 Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705 Da Fonseca, Leonardo G.|||0000-0002-0216-3618 Llarch, Neus|||0000-0003-3209-0453 Iserte, Gemma|||0000-0003-3908-8743 Guedes, Cassia Muñoz-Martínez, S.|||0000-0003-0663-0575 Darnell, Anna Belmonte, Ernest|||0000-0003-3572-9769 Rimola, Jordi|||0000-0002-1814-4198 Forner, Alejandro|||0000-0002-9014-4950 Ayuso, Carmen|||0000-0002-9606-6957 Bruix, Jordi|||0000-0002-9826-0753 Reig, María|||0000-0002-5711-9534 |
| author_role |
author |
| author2 |
Sapena, Victor|||0000-0003-4379-6486 Boix, Loreto|||0000-0002-6015-3901 Torres, Ferran|||0000-0002-7355-7913 Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705 Da Fonseca, Leonardo G.|||0000-0002-0216-3618 Llarch, Neus|||0000-0003-3209-0453 Iserte, Gemma|||0000-0003-3908-8743 Guedes, Cassia Muñoz-Martínez, S.|||0000-0003-0663-0575 Darnell, Anna Belmonte, Ernest|||0000-0003-3572-9769 Rimola, Jordi|||0000-0002-1814-4198 Forner, Alejandro|||0000-0002-9014-4950 Ayuso, Carmen|||0000-0002-9606-6957 Bruix, Jordi|||0000-0002-9826-0753 Reig, María|||0000-0002-5711-9534 |
| author2_role |
author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Diarrhoea Hepatocellular carcinoma Resistance Sorafenib Survival Tyrosine kinase inhibitor |
| topic |
Diarrhoea Hepatocellular carcinoma Resistance Sorafenib Survival Tyrosine kinase inhibitor |
| description |
Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2 2021-01-01 2021 2021-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/256487 https://dx.doi.org/urn:doi:10.1002/ueg2.12111 |
| url |
https://ddd.uab.cat/record/256487 https://dx.doi.org/urn:doi:10.1002/ueg2.12111 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.relation.none.fl_str_mv |
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 CM15/00050 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19/00222 Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI13/01229 Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI15/00145 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/00542 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/00768 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/0358 |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-sa/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-sa/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869404380314206208 |
| score |
15,198674 |